Resvega, a Nutraceutical Preparation, Affects NFκB Pathway and Prolongs the Anti-VEGF Effect of Bevacizumab in Undifferentiated ARPE-19 Retina Cells
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Age-related macular degeneration (AMD) is an irreversible chronic degenerative pathology that affects the retina. Despite therapeutic advances thanks to the use of anti-vascular endothelial growth factor (VEGF) agents, resistance mechanisms have been found to accentuate the visual deficit. In the present study, we explored whether a nutraceutical formulation composed of omega-3 fatty acids and resveratrol, called Resvega®, was able to disrupt VEGF-A secretion in human ARPE-19 retina cells. We found that Resvega® inhibits VEGF-A secretion through decreases in both the PI3K-AKT-mTOR and NFκB signaling pathways. In NFκB signaling pathways, Resvega® inhibits the phosphorylation of the inhibitor of NFκB, IκB, which can bind NFκB dimers and sequester them in the cytoplasm. Thus, the NFκB subunits cannot migrate to the nucleus where they normally bind and stimulate the transcription of target genes such as VEGF-A. The IκB kinase complex (IKK) is also affected by Resvega® since the nutraceutical formulation decreases both IKKα and IKKβ subunits and the IKKγ subunit which is required for the stimulation of IKK. Very interestingly, we highlight that Resvega® could prolong the anti-angiogenic effect of Avastin®, which is an anti-VEGF agent typically used in clinical practice. Our results suggest that Resvega® may have potential interest as nutritional supplementation against AMD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






![Figure 7 Schematic illustration of the novel proposed mechanisms of the anti-angiogenic impact of Resvega® (RGA), which is able to target several angiogenesis molecular pathways in human ARPE-19 retina cell model. RGA counteracts angiogenic VEGF-A production through an alteration of the AKT/PI3K and NFκB pathways. In detail, RGA reduces the regulator complex IKK controlling the downstream NFκB subunits P65 and P50 belonging and their nuclear/cytosolic localization. This new RGA-targeted pathway complements data on the impact of RGA, which we have previously demonstrated to be involved in preventing activation of the MAPK signaling pathway in ARP19 cells [22]. The disruption of these two important angiogenesis signaling pathways likely leads to a sensitization of retina cells to the anti-VEGF treatment, resulting in an increased ability of Avastin® to decrease VEGF-A secretion over time.](https://figures.cochat.ai/paper-figures/d5e494ebbbf04e5da33e63240a60350c/resvega-a-nutraceutical-preparation-affects-nfb-pathway-and-prolongs-the-anti-figure-7.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Nutritional anti-VEGF intervention against wet AMD has been shown to act by preventing MAPK activation in RPE cells [ 54 ], with the involvement of NFκB [ 55 ]”
From MAPK Pathways in Ocular Pathophysiology: Potential Therapeutic Drugs and Challenges (2023) · cites this paper as [55]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
De Cillà, S. D., Farruggio, S., Vujosevic, S., Raina, G., Filippini, D., Gatti, V., Clemente, N., Mary, D., Vezzola, D., Casini, G., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479441 · Cited by 5,136
A cytokine-responsive IκB kinase that activates the transcription factor NF-κB
DiDonato, J. A., Hayakawa, M., Rothwarf, D. M., Zandi, E., & Karin, M. (1997) · Nature · doi:10.1038/41493 · Cited by 2,125
IKK-1 and IKK-2: Cytokine-Activated IκB Kinases Essential for NF-κB Activation
Mercurio, F., Zhu, H., Murray, B. W., Shevchenko, A., Bennett, B. L., Li, J. W., Young, D. B., Barbosa, M., Mann, M., Manning, A., et al. (1997) · Science · doi:10.1126/science.278.5339.860 · Cited by 2,040
Age-related macular degeneration
Lim, L. S., Mitchell, P., Seddon, J. M., Holz, F. G., & Wong, T. Y. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60282-7 · Cited by 1,717
ARPE-19, A Human Retinal Pigment Epithelial Cell Line with Differentiated Properties
DUNN, K. C., AOTAKI-KEEN, A. E., PUTKEY, F. R., & HJELMELAND, L. M. (1996) · Experimental Eye Research · doi:10.1006/exer.1996.0020 · Cited by 1,330 · cited 1×
“These undifferentiated ARPE-19 cells spontaneously produce human RPE cell lines with normal karyology, which form polarized epithelial monolayers [44].”
BackgroundYamaoka, S., Courtois, G., Bessia, C., Whiteside, S. T., Weil, R., Agou, F., Kirk, H. E., Kay, R. J., & Israël, A. (1998) · Cell · doi:10.1016/s0092-8674(00)81466-x · Cited by 1,076
Fukumura, D., Gohongi, T., Kadambi, A., Izumi, Y., Ang, J., Yun, C.-O., Buerk, D. G., Huang, P. L., & Jain, R. K. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.041359198 · Cited by 1,020 · cited 2×
“These include, in particular, the ERK1/2 pathway on which we have shown that RGA has an effect [22], but also other pathways, for instance the PI3K‐AKT‐mTOR pathway, which is crucial for cell survival, regulation of vasomotion and angiogenesis [27,28] In order to understand the impact of RGA on Figure 1.”
BackgroundAge-related macular degeneration
Fleckenstein, M., Keenan, T. D. L., Guymer, R. H., Chakravarthy, U., Schmitz-Valckenberg, S., Klaver, C. C., Wong, W. T., & Chew, E. Y. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00265-2 · Cited by 978
IKK-γ is an essential regulatory subunit of the IκB kinase complex
Rothwarf, D. M., Zandi, E., Natoli, G., & Karin, M. (1998) · Nature · doi:10.1038/26261 · Cited by 957
Age-related macular degeneration (AMD): pathogenesis and therapy.
Nowak, J. Z. (2006) · PubMed · Cited by 755
Cited by
MAPK Pathways in Ocular Pathophysiology: Potential Therapeutic Drugs and Challenges
Moustardas, P., Aberdam, D., & Lagali, N. (2023) · Cells · doi:10.3390/cells12040617 · Cited by 63
“At the same time, a balanced p38/TXNIP/NFκB pathway inhibition is required for proper tight junctions in the inner blood–retinal barrier [87] and for the prevention of macular edema [88–91], while ERK and JNK phosphorylation is inversely correlated with the expression of tight junction components in human retinal endo…”
BackgroundInfluentialBuonfiglio, F., Korb, C. A., Stoffelns, B. M., Pfeiffer, N., & Gericke, A. (2024) · Aging and Disease · doi:10.14336/ad.2024.0124 · Cited by 54
“This group further showed a prolonged effect of bevacizumab in undifferentiated ARPE-19 cells through supplementation with Resvega®, suppressing VEGF-A secretion by attenuating both the PI3K/Akt/mTOR and NFκB signaling pathways [424].”
The Past and Future of Angiogenesis as a Target for Cancer Therapy and Prevention
Albini, A., Noonan, D. M., Corradino, P., Magnoni, F., & Corso, G. (2024) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-24-0085 · Cited by 25
Huang, J.-M., Zhao, N. R., Hao, X.-N., Li, S., Wei, D., Pu, N., Peng, G.-H., & Tao, Y. (2024) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.65.1.29 · Cited by 22
Pinelli, R., Ferrucci, M., Berti, C., Biagioni, F., Scaffidi, E., Bumah, V. V., Busceti, C. L., Lenzi, P., Lazzeri, G., & Fornai, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108979 · Cited by 9
Metadata
- Authors
- Sghaier, R., Perus, M., Cornebise, C., Courtaut, F., Scagliarini, A., Olmiere, C., Aires, V., Hermetet, F., & Delmas, D.
- Affiliations
- Inserm (FR)
- Laboratoires Théa<sup>®</sup>, 12 Rue Louis-Blériot, 63000 Clermont-Ferrand, France
- Corresponding author
- Delmas, Dominique
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-10-03
- Volume
- 23
- Issue
- 19
- Pages
- 11704
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC9569823
- OpenAlex
- W4303699621
- Cited by
- 11
- References
- 45
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 3 · 2023: 3
- FWCI
- 2.01
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Agence Nationale de la Recherche (ANR-11-LABX-0021)
- Association Nationale de la Recherche et de la Technologie
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- nutraceuticals, resveratrol, omega-3 fatty acids, age-related macular degeneration, VEGF-A secretion, NF-κB signaling, PI3K/AKT/mTOR pathway, IκB phosphorylation, IκB kinase, bevacizumab, ARPE-19 cells, dietary supplementation
- MeSH terms
- Bevacizumab, Resveratrol, Humans, Macular Degeneration, Retina, Fatty Acids, Omega-3, Endothelial Growth Factors, NF-kappa B, Dietary Supplements, Phosphatidylinositol 3-Kinases, Vascular Endothelial Growth Factor A, Proto-Oncogene Proteins c-akt, I-kappa B Kinase, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Resvega, a Nutraceutical Preparation, Affects NFκB Pathway and Prolongs the Anti-VEGF Effect of Bevacizumab in Undifferentiated ARPE-19 Retina Cells. https://app.cochat.ai/papers/10.3390/ijms231911704
- The paper
- Sghaier, R., Perus, M., Cornebise, C., Courtaut, F., Scagliarini, A., Olmiere, C., Aires, V., Hermetet, F., & Delmas, D. (2022). Resvega, a Nutraceutical Preparation, Affects NFκB Pathway and Prolongs the Anti-VEGF Effect of Bevacizumab in Undifferentiated ARPE-19 Retina Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms231911704
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.